BCG Shortage — What to Do If It Is Unavailable

Because BCG is grown, not manufactured. It is a live bacterium. Every batch has to be cultured, freeze-dried and release-tested, which takes months. Very few facilities in the world make it. It is inexpensive, so there is little commercial reason to build more capacity. One interruption at one site removes a large share of world supply.

That single fact explains almost everything else on this page. A shortage of a chemical tablet can be met by running the production line harder. A shortage of a living culture cannot. This is why guideline bodies respond to BCG shortages by publishing rationing advice rather than by promising more supply.

• It is a living product — bacteria are cultured, freeze-dried, then held for batch release testing. A failed or contaminated batch is destroyed, and the months that went into it are lost with it.
• Very few producers — a handful of facilities supply most of the world. When one stops for maintenance, contamination or a regulatory hold, there is no spare capacity waiting elsewhere.
• The price works against supply — BCG is among the cheapest agents in cancer care. Thin margins mean little incentive to invest in new plant, and that has been true for decades.
• Demand kept rising — as BCG became the usual recommendation for more risk groups, the number of instillations needed each year grew faster than production did.
• Allocation and distribution — the same organism is used for childhood tuberculosis immunisation, and supply is divided between programmes, states and hospitals. A centre can be out of stock in a month when the country is not.

India is one of the world’s producers of BCG, so a complete national absence is not the usual Indian experience. What patients here meet far more often is a local gap: this hospital’s stock, this month’s allocation, or a batch waiting on release testing. Ask your urology team which of those three it is. The answer decides whether you are waiting two weeks or changing plan.

A shortage is a supply problem, not a verdict on your cancer. Nothing about your pathology has changed because a fridge is empty.

Risk categories follow those used in current NCCN and ESMO guidance and applied in Indian practice. This table is orientation for the conversation with your urologist, not an allocation, and no option here is presented as performing better than another. Availability statements are as of August 2026.

A reduced dose is a rationing measure, not a downgrade you are being handed. During shortages, NCCN and ESMO guidance accepts dividing a vial between patients treated on the same day, shortening maintenance, and reserving full-dose BCG for the highest-risk disease. Whether a smaller dose protects as well as a full one is not settled, and depends on the risk group studied.

It helps to know what a reduced dose actually means on the day. It does not mean a weaker or different product. One vial is divided between patients scheduled together, so the same material treats more people. The catheter, the dwell time and the checks before the instillation are unchanged. What changes is how much of the organism goes in, and sometimes how many maintenance rounds you are offered.

These are the rationing strategies guideline bodies have set out during international shortages. Your urologist chooses between them; none of them is something you can pick off a menu.

• Prioritise by risk — high-risk disease is treated first with the supply that exists. Intermediate-risk patients are more likely to be moved to intravesical chemotherapy.
• Divide the vial — patients booked on the same day share one vial, so the same stock covers more courses.
• Shorten maintenance — the maintenance phase is cut back rather than the induction course, because induction is what is being protected.
• Stop using it where it was optional — low-risk patients who were only ever a discretionary indication are moved to chemotherapy or to surveillance alone.
• Switch class rather than wait indefinitely — an open-ended wait for stock that may not arrive is itself a decision, and your team weighs it against changing to something available now.

What does not change during a shortage: the checks before each instillation, the instruction to report urinary symptoms and fever before your next dose, and your cystoscopy schedule. If anything, surveillance matters more when the treatment plan has been disturbed.

This page makes no claim that a reduced dose performs as well as, or worse than, a full dose. That comparison is genuinely unresolved and belongs to your treating urologist, working from your pathology and your risk group.

Not through an online listing or an unverified seller, no. BCG is a live biological. It needs an unbroken cold chain and has to be instilled by a trained team through a catheter. Material that has been warmed, expired, repacked or falsified can be dangerous when it is put into a bladder that was recently resected.

The urge to go looking is understandable. A family told that stock has run out, watching weeks pass, will search. What they find are sellers who cannot show where the product has been. Counterfeit cancer medicines have been reported entering Indian supply chains, and a shortage is exactly the condition that lets them in. This is not a reason to panic. It is a reason to keep sourcing inside the hospital system.

• Let the hospital procure it — ask your urology unit to source through hospital procurement or a recognised distributor, including from another centre if that is what it takes.
• Ask for the batch number and expiry — and ask that both are recorded in your file before the instillation.
• Do not accept product you transported yourself — an unbroken cold chain cannot be assumed after a bus or a flight.
• Treat anything offered outside a hospital as unsafe — a pharmacy listing, a courier offer or a social-media seller is not a supply chain.
• Report a broken cold chain — if a vial has been out of refrigeration, say so before it is used, not afterwards.

If you have already been given material sourced outside the hospital, tell your urology team before your next instillation. If you develop a fever with shaking chills, or a fever above 38.5 degrees Celsius lasting beyond 48 hours after an instillation, seek medical attention the same day and say that you have had intravesical BCG. Call 1800 202 8726 if you need help finding care.

Usually more, and that is the part families feel first. BCG is among the least costly treatments in cancer care. Almost anything used in its place costs more per cycle, and the newer intravesical approaches cost considerably more where they are available at all. A supply problem quietly becomes a money problem, and nobody says so out loud.

Scheme and insurance cover follows what is actually given, not what was originally planned. A switch can change your position under Aarogyasri, CGHS, ECHS or a cashless policy even when the appointment looks the same. Ask three questions before you agree: what does the new plan cost per cycle, what is covered, and what will you pay out of pocket across the whole course. Ask for the answers in writing. Any figure quoted to you anywhere is indicative only, as of August 2026, and varies by centre.

If cost is the reason you are thinking of stopping, say so plainly to your team rather than quietly missing appointments. A shortened schedule you complete is a different situation from a full schedule you cannot afford to attend, and your urologist can only plan around what they know.

It is also worth knowing where BCG sits among immune treatments generally, because the vocabulary confuses people. BCG is vaccine-derived, but it is not a cancer vaccine in the sense the news uses that word. Therapeutic cancer vaccines: what exists today sets out what is approved and what is still confined to trials, and mRNA cancer vaccines: what the headlines actually mean covers the class most often confused with BCG in family conversations.

• Therapeutic Cancer Vaccines: What Exists Today — what a treatment vaccine is, what is approved, and what is still confined to trials.
• mRNA Cancer Vaccines: What the Headlines Actually Mean — the class families read about most, and where it genuinely stands today.
• HPV and Hepatitis B Vaccination: Preventing Cancer, Not Treating It — the difference between a vaccine that prevents a cancer and one used to treat one.
• Immunotherapy at CION Cancer Clinics — the hub page: biomarker testing, day-care administration, monitoring and support in one place.

This page explains a supply problem and the options around it from a scientific standpoint. It is general information, not a treatment recommendation, and not a substitute for consultation with your own urologist and oncologist. No product, brand or manufacturer is named or endorsed here, and no option is presented as performing better than another. Immunotherapy is administered as day care at CION centres; response-assessment PET-CT is coordinated at partner imaging centres. CION does not provide CAR-T or cell therapy. Any cost mentioned is indicative only, as of August 2026. Only your treating team, reviewing your complete case, can say what applies to you.

Families are asking this question every week

A cancelled instillation is frightening in a way the appointment slip never explains. Thousands of families have sat in our rooms with a plan that changed. You can too.